CEO of Roche warns that lots of Mpox cases in Europe are not being reported!

Medical News: The CEO of the Swiss pharmaceutical giant Roche, Thomas Schinecker, has raised alarms about the possibility of underreported cases of Mpox (formerly known as Monkeypox) across Europe. Speaking during a recent company earnings call, Schinecker indicated that the actual number of mpox cases in Europe might be far higher than what official reports suggest.
https://www.reuters.com/world/europe/roche-ceo-says-more-mpox-cases-likely-be-reported-europe-2024-10-23/
 
He emphasized that although some cases are making headlines, many others might be slipping under the radar.


CEO of Roche warns that lots of Mpox cases in Europe are not being reported!

Schinecker's comments come at a time when Europe is grappling with a potential new variant of Mpox. For example, Germany's public health authority, the Robert Koch Institute, has confirmed the discovery of a new Mpox variant belong to the clade 1b in the country, though it has assessed the risk to the general public as low. Nonetheless, the identification of this new strain has sparked concerns about its possible spread and the critical need for accurate reporting and timely testing.
 
It is believed that the spread of the Mpox Clade 2b variant is spreading at exponential rate especially among the gay and bisexual communities across Europe but various governments and health authorities are not releasing the true data of this rise in infections and there is literally no mainstream media covering Medical News updates on the mpox situation.
 
Roche's Preparedness and Capacity for Testing
As one of the global leaders in diagnostic tools, Roche is well-prepared to respond to any increase in demand for mpox testing. Schinecker revealed that Roche has the capacity to produce up to ten times the current amount of mpox testing kits, if required. This preparedness could prove essential if the virus begins to spread more widely, a scenario Roche is closely monitoring. According to Schinecker, the company can scale up production of test kits within six to nine months if necessary, which provides a significant level of readiness should the situation worsen.
 
Schinecker stressed as to how the underreporting of mpox cases could complicate efforts to contain the virus and reduce transmission rates. The ability to diagnose and isolate cases quickly will be crucial in preventing further spread, particularly given the new variant that has emerged in Germany.
 
The History of Mpox: Understanding the Disease
Mpox was first discovered in 1958 when outbreaks occurred among colonies of monkeys kept for research, which is how the disease got its name. However, the first human case was not reported until 1970, when it was identified in the Democratic Republic of Congo (DRC). For decades, mpox has been endemic to Central and West Africa, where it primarily spreads from animals to humans through close contact.
 
The virus belongs to the same family as smallpox but is generally less severe. It is primarily transmitted through close contact, bodily fluids, respiratory droplets, or contaminated materials like bedding and clothing. Symptoms typically include fever, body aches, swollen lymph nodes, and a characteristic rash that often spreads from the face to other parts of the body. The rash progresses into painful lesions filled with pus, which can leave permanent scars. In severe cases, especially among children and individuals with weakened immune systems, mpox can be fatal, with a case fatality rate ranging from 1% to 10%.
 
Despite being geographically contained for many years, mpox has recently spread to other parts of the world, including Europe and the Americas, prompting international concern. Mpox was declared a global health emergency in August 2022 following the discovery of a new variant in the DRC, which subsequently spread to other countries, including Sweden, Thailand, and Germany.
 
The Global Spread of Mpox
The spread of mpox beyond its traditional geographic regions has raised new challenges for global health authorities. For years, the virus had been primarily confined to Central and West Africa, where it was considered endemic. However, in recent years, mpox has been increasingly reported in countries that had previously seen few or no cases, including those in Europe and the Americas. This spread has been particularly troubling because it has coincided with the emergence of new variants, which might complicate containment efforts.
 
In Europe, several cases have already been confirmed, including in Germany and Sweden. Some experts believe that more cases are likely to be confirmed in the coming weeks, especially as testing increases. Roche's ability to produce a high number of testing kits will be crucial in detecting and managing potential outbreaks. However, public awareness and vigilance will also be key in reducing the spread of mpox.
 
The recent appearance of the new mpox variant in Germany adds an additional layer of concern. While the Robert Koch Institute has assured the public that the general risk remains low, the emergence of a variant highlights the virus's potential for mutation and spread.
https://www.msn.com/en-xl/news/other/new-mpox-variant-detected-in-germany-health-authority/ar-AA1sI0zS
 
This means that even though current measures might be sufficient for now, the situation could change rapidly if the virus begins to evolve in ways that make it more contagious or more severe.
 
The Role of Roche in Managing the Mpox Crisis
Roche has played a critical role in developing diagnostic tools to detect and manage viral outbreaks, including mpox. During the 2022 outbreak, Roche quickly developed PCR tests to detect the virus, a tool that proved invaluable in tracking and managing the spread of the disease. Now, with a new variant emerging, the company's role is more important than ever.
 
Schinecker has emphasized that Roche is ready to increase production of its testing kits as needed. Currently, demand for testing is low, but the company’s capacity to increase output by tenfold within months demonstrates a high level of preparedness. This readiness is crucial in ensuring that testing capabilities will not be a bottleneck in the fight against mpox, especially if the virus begins to spread more rapidly or if new, more dangerous variants emerge.
 
Conclusion: Vigilance and Preparedness Are Key
As the world continues to recover from the COVID-19 pandemic, it is clear that we must remain vigilant against other viral threats like mpox. The recent underreporting of cases in Europe, along with the emergence of a new variant, underscores the need for greater transparency, better reporting mechanisms, and increased testing. Roche’s ability to rapidly scale up production of test kits is reassuring, but it is only one piece of the puzzle.
 
Preventing a full-blown epidemic will require coordinated efforts from public health authorities, governments, and the pharmaceutical industry. Public awareness campaigns, widespread testing, and rapid response measures will be critical in controlling the spread of mpox. Additionally, the role of accurate data cannot be overstated. Only by having a clear understanding of the true scope of the outbreak can effective measures be put in place to protect public health.
 
For the latest Mpox news, keep on logging to Thailand Medical News.
 
Read Also:
https://www.thailandmedical.news/news/mpox-causes-48-individuals-to-be-hospitalized-in-australia-while-cases-continue-to-rise-in-victoria-and-new-south-wales
 
https://www.thailandmedical.news/news/94-confirmed-mpox-cases-and-1297-suspected-cases-reported-in-nigeria